RE: NovaTalk: COVID-19 Mutations, the Ultimate Test8 May 2021 07:05
The discussion was eye opening to a certain extent.
It was good that Matt HanCo@k was watching as it leaves the Government in no doubt that a layered approach will be required for evermore.
Choices we make will define the outcome but essentially vaccination, testing and screening will remain along with containment in severe break out situations as we learn to live with the virus.
Vaccination > Testing > Social Responsibility
Any notion that LFT will replace PCR is dead in the water as both testing methods are essential.
Vaccination > Even those vaccinated can spread the virus albeit in reduced numbers. The shocking reality that even in the USA after the initial surge of people coming forward wanting the vaccine the take up rate is dropping off due to people NOT wanting to be vaccinated. We are talking nearly half the population and that’s in a considered developed nation, so the Virus and variants will continue to spread and evolve.
Testing > LFT Like raking the lawn for leaves, we need to keep doing it over and over quickly to find as many cases as possible BUT they still need to be then verified by PCR to identify what they are. The more cases identified the more PCR required. PCR is absolutely essential. We need to keep on top of variants especially Variants of Concern as they can undermine the vaccine and may be more contagious as already identified. We need to then support sequencing to stay ahead of the VOCs.
Social Responsibility > Containment would be required in outbreaks. The world is not safe until we are all safe. Those vaccinated can still spread the virus. More people need to come forward for vaccination. If everyone socially distanced, it would help eradicate the virus but that is not a reality hence we have to learn to live with it.
The key take for Novacyt investors is that we have all bases covered for our supply chains with both PCR and LFTs and demand will remain.
Diagnostics is here to stay, and the UK is a WORLD leader. In my considered opinion Novacyt’s diagnostics will continue to evolve as they are ahead of the curve on R&D and as such revenues will continue and become proven and the business ultimately will be re-rated properly as such.
I am pro biased for Novacyt I accept; however, this really is a golden opportunity to hold shares here like no other. The discussion only endorses my belief of the importance of Novacyt on the world stage. As I said before Novacyt is History in the Making.
Soon the market will not ignore the investment opportunity here imo.
GLA